What top creators are saying about UnitedHealth Group Incorporated(UNH)

Cited as a legacy incumbent facing 2025 medical loss ratio issues, used as a negative contrast to more efficient disruptors.

Experienced a 22% drop following disappointing earnings, signaling immediate volatility in the healthcare sector.

Noted for rapid price increase ('vertical candle') following a successful portfolio call.

Sold by Berkshire Hathaway indicating institutional divestment

Facing market skepticism and sector-wide valuation compression; may struggle to implement AI efficiencies as quickly as smaller competitors.

Growing public appetite for healthcare reform and international drug pricing models poses a risk to private insurance providers.

Strong earnings beat and ability to reprice premiums to offset medical costs; viewed as a turnaround play.

Touched the lower boundary of a secular trend channel dating back to the 1990s; seen as a core holding for stability and dividends.

Stock surged 10% after a significant earnings beat and conservative previous guidance.

Performing very well in the current environment and included as a portfolio winner.

Has performed well recently; benefits from disinflation in medical care commodities which provides a tailwind for managed care providers.

Suffered from rising costs, though saw a relief rally following revised Medicare Advantage pricing.

Stock jumped 9% following a favorable government rate increase to 2.48%.

Facing structural challenges in Optum division, aggressive risk coding scrutiny, and regulatory headwinds regarding flat rate updates.

Berkshire Hathaway made no changes to its position in Q4, holding its stake steady.

Mentioned as part of a sector with a very bearish outlook where business models have collapsed, and problems are widespread, not just confined to UNH.

A sponsored advertisement highlighted the company's focus on innovating healthcare delivery, which aligns with major investment themes like value-based care and preventative medicine.

By positioning itself as a solution to rising healthcare costs in a paid advertisement, the company is aligning its brand with the needs of a system under financial stress, which could be a key factor for future growth and market share.

Mentioned as a sponsor of the podcast in a paid advertisement that highlighted the company's work in innovating healthcare delivery. This was not an editorial investment analysis.

Mentioned as an example of the negative impact of the political climate focused on lowering drug costs, as its stock dropped on news it couldn't raise prices.

The outlook is highly bearish due to regulatory headwinds (a 0.09% Medicare Advantage pricing increase) and deep-seated business challenges, including a 41% EPS drop, declining revenue guidance, and collapsing margins at its OptumHealth division.

The stock dropped nearly 20% following the news of lower Medicare Advantage payment rates and a simultaneous earnings miss, creating a significant challenge for the stock and pressure on profitability.

Advised to 'stay away' from due to stock volatility and 'significant risk' from a political overhang related to healthcare affordability.

Stock dropped significantly due to insufficient Medicare Advantage rate increases. The company is considered particularly vulnerable and one of the 'most aggressive risk coders,' making it disproportionately impacted by a government crackdown on these practices.

The stock faces significant headwinds from slowing growth and unfavorable government policy changes regarding Medicare Advantage payments, with a projection for its first annual revenue drop in decades.

Presents a bearish long-term outlook due to deep, structural problems and significant regulatory risk, as its profitability is at the mercy of decisions by the Centers for Medicare & Medicaid Services (CMS).

A large stock sale by a member of Congress followed by a nearly 20% price drop suggests a strong bearish signal. The company's profitability is at risk from potential government policy changes to Medicare reimbursement models.

Dropped over 8% after-hours on news of a proposed Medicare Advantage rule change for 2027 with a much lower-than-expected rate increase, seen as a major headwind for profitability.

Listed as a major company with a 'huge earnings week' ahead, and should be watched for potential market-moving news.

As a prominent example of vertical integration, the company faces significant regulatory, political, and antitrust risk. Its business model is being challenged, exposing it to headline risk and potential legislative action that could force divestitures.

It is suggested that the company's problems may be 'deeply structural' and go beyond near-term cost issues, implying a bearish long-term outlook for its business model.

Faces a major disruptive threat to its PBM business model from a government policy to move more prescription drugs to over-the-counter status, which would reduce prescription volume and fees.

Portrayed as a primary example of the sector's problems, hit hard by Medicare Advantage rule changes, and its vertical integration strategy is framed as monopolistic and anti-competitive, presenting significant regulatory and reputational risks.

Not recommended for bottom-fishing as its long-term uptrend is considered broken, unlike pharma and biotech stocks in the same sector.

Identified as one of the worst performers from 2025 that has a good chance to rebound in 2026, making it a potential turnaround play.

Showed significant declines at -34.74%, suggesting potential areas for caution or short opportunities.

Proactively managing the risk of drug pricing regulation by publicly marketing its efforts to save consumers money, which builds goodwill and could aid customer retention.

Part of the worst-performing healthcare subsector (medical insurance) due to higher-than-expected cost increases; the stock was down 33%.

The company is proactively managing political and social risks by working to lower prescription drug costs, which could build a competitive advantage, customer loyalty, and a more sustainable business model.

Faces significant headwinds from expiring ACA subsidies, which could shrink its customer base. The company is experiencing extreme negative public sentiment and high reputational risk due to rising healthcare costs.

Mentioned as a potential 'buy the dip' opportunity after a significant sell-off, representing an attractive entry point for investors bullish on the U.S. healthcare industry.

Gained 2-3% on news of a potential extension of ACA subsidies, which is viewed as a positive catalyst for the managed care sector.

Specifically named in a very negative light, with the podcast suggesting a 'corrupt flow of money' between the government and the insurance giant, highlighting significant reputational risk.

Cited as an example of a defensive healthcare stock that investors may rotate into during periods of tech weakness.

Mentioned as a healthcare/defensive name that is seeing inflows as part of a healthy market rotation away from tech stocks.

Sentiment is very bullish as the stock is one of the top three being bought by institutional investors according to 13F filings and is showing very strong price momentum.

Stock was down 2.6% due to uncertainty surrounding the extension of ACA subsidies, which was delayed in the government shutdown deal.

An agreement to extend ACA subsidies, which is considered likely, would be a bullish catalyst as it would help maintain its customer base.

Mentioned as a notable strong performer indicating positive market sentiment.

Reported strong earnings and provided better-than-expected guidance, signaling to the market that its focus on profitability and margin recovery is on the right track.